調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Dermatological Drugs Market Forecast 2014-2024

皮膚科治療薬市場（2014-2024）

◆タイトル：Dermatological Drugs Market Forecast 2014-2024
◆商品コード：Visiongain-405316
◆調査・発行会社：visiongain
◆発行日：2014年4月
◆ページ数：272
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）

Single user licence（1名使用）	GBP1,799 ⇒換算￥266,252	見積依頼/購入/質問フォーム
Dept Licence（部署内共有可）	GBP2,999 ⇒換算￥443,852	見積依頼/購入/質問フォーム
Site Licence（同一国内社内共有可）	GBP4,999 ⇒換算￥739,852	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"皮膚科治療薬市場（2014-2024）"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Dermatological drugs – new study showing you trends, R&D progress, and predicted revenues
Where’s the dermatological drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 272-page report provides 169 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA
• Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-Öschelbronn, Germany
• Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
• Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG, Leverkusen, Germany
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these five submarkets:
• Psoriasis
• Skin infection drugs
• Acne
• Dermatitis
• Other treatments.
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 28 products, including these brands:
• Humira
• Enbrel
• Stelara
• Cubicin
• Zyvox
• Claravis
• Epiduo
• Bepanthen
• Protopic
Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World
There will be growth in established pharma markets and in developing countries. Our analyses show that India, Brazil, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.
Leading companies and potential for market growth
Overall world revenue for dermatological drugs will reach $24.1bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs and antibacterial drug resistance will increase sales to 2024.
Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
• Galderma
• Johnson & Johnson
• AbbVie
• GSK
• Pfizer
• LEO Pharma
A company profile gives you the following information:
• Revenue forecast for dermatological drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You will see trends for these areas:
• Psoriasis
• Skin infection drugs
• Acne
• Dermatitis
• Other progress in dermatology.
Our study also discusses these agents and technologies, among others:
• Drug delivery
• Oral drug candidates
• Novel small molecules
• Photodynamic therapy.
Dermatology holds strong, promising R&D. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.
What issues will affect the dermatological drugs industry?
Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses:
• Increasing demand for dermatological drugs due to demographic trends
• A strong R&D pipeline
• Patent expiry and generic competition
• Growth areas such as skin infections, onychomycosis and melanoma
• Advances in topical drug delivery
• Personalised dermatology and genomics
• Pricing and reimbursement issues
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Dermatological Drugs: World Market Prospects 2014-2024 & Future Prospects for Leading Companies report helps you
In summary, our 272-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world dermatological drugs market and 4 product categories (therapeutic classes) market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 6 leading companies – hear about products, results and strategies including revenue forecasts for dermatological drugs to 2024
• Predicted revenues of 28 leading drugs to 2024 – see potentials of top products
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

【レポートの目次】

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.5 Glossary of Terms in this Report
2. Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 An Overview of Dermatology
2.2.1 The Structure of the Skin, Hair and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes and Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation of the Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases of Clinical Trials
2.12 Dermatological Drugs in This Report
3. Dermatological Drugs: World Market 2014-2024
3.1 The World Dermatological Drugs Market in 2012 and 2013
3.1.1 Leading Dermatological Drugs
3.1.2 Leading Companies in the Dermatological Drugs Market
3.2 World Dermatological Drugs Market: Sales Forecast 2014-2024
3.3 Psoriasis Drugs Lead the World Dermatological Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.5 World Dermatological Drugs Market: Drivers and Restraints 2014-2024
3.6 Opportunities for Blockbuster Sales
4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Dermatological Drugs Market
4.2 World Dermatological Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Dermatological Drugs Market 2014-2024
4.3.1 US Dermatological Drugs Market Forecast 2014-2024
4.3.2 US Dermatological Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Dermatological Drugs Market 2014-2024
4.4.1 Japanese Dermatological Drugs Market Forecast 2014-2024
4.4.2 Japanese Dermatological Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.5 Chinese Dermatological Drugs Market 2014-2024
4.5.1 Chinese Dermatological Drugs Market Forecast 2014-2024
4.5.2 Chinese Dermatological Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Rapid Advancement of Dermatology in China
4.5.2.3 Price Controls and the Anhui Model
4.6 EU5 Dermatological Drugs Market 2014-2024
4.6.1 German Dermatological Drugs Market Forecast 2014-2024
4.6.2 French Dermatological Drugs Market Forecast 2014-2024
4.6.3 UK Dermatological Drugs Market Forecast 2014-2024
4.6.4 Italian Dermatological Drugs Market Forecast 2014-2024
4.6.5 Spanish Dermatological Drugs Market Forecast 2014-2024
4.7 Indian Dermatological Drugs Market 2014-2024
4.7.1 Indian Dermatological Drugs Market Forecast 2014-2024
4.7.2 Indian Dermatological Drugs Market: Trends and Developments
4.7.2.1 Drug Prices Control Order 2013
4.7.2.2 Expansion of Healthcare Provision
4.8 Brazilian Dermatological Drugs Market 2014-2024
4.8.1 Brazilian Dermatological Drugs Market Forecast 2014-2024
4.8.2 Brazilian Dermatological Drugs Market: Trends and Developments
4.8.2.1 Increasing Access to Medicines
4.9 Russian Dermatological Drugs Market 2014-2024
4.9.1 Russian Dermatological Drugs Market Forecast 2014-2024
4.9.2 Russian Dermatological Drugs Market: Trends and Developments
4.9.2.1 Pharma2020, Healthcare and Industry Reform
4.10 Mexican Dermatological Drugs Market 2014-2024
4.10.1 Mexican Dermatological Drugs Market Forecast 2014-2024
4.10.2 Mexican Dermatological Drugs Market: Trends and Developments
4.10.2.1 Seguro Popular: Mexican Healthcare Reform
4.10.2.2 International Interest in Mexico
5. Psoriasis Drugs Market 2014-2024
5.1 Drugs for Psoriasis: The Success of Biologics
5.2 Leading Products in the Psoriasis Drug Market in 2012 and 2013
5.3 Psoriasis Drugs: Trends and Developments
5.3.1 Biological Drugs: An Overview
5.3.1.1 Disadvantages of Biologics
5.4 Psoriasis Drugs: Market Forecast 2014-2024
5.5 Market Share of Leading Psoriasis Drugs to 2024
5.6 Humira (adalimumab, AbbVie)
5.6.1 Humira: Sales Forecast 2014-2024
5.6.2 Prospects for Biosimilar Humira
5.7 Enbrel (etanercept, Amgen/Pfizer)
5.7.1 Enbrel: Sales Forecast 2014-2024
5.7.2 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
5.7.3 Competition from Other Drugs
5.7.4 Biosimilar Competition for Enbrel
5.8 Stelara (ustekinumab, Johnson & Johnson)
5.8.1 Stelara: Sales Forecast 2014-2024
5.8.2 Competition for Stelara in the Pipeline
5.9 Remicade (infliximab, Johnson & Johnson)
5.9.1 Remicade: Sales Forecast 2014-2024
5.10 Daivobet (betamethasone/calcipotriene, LEO Pharma)
5.10.1 Daivobet: Sales Forecast 2014-2024
5.10.2 LEO Pharma’s Life Cycle Management of Daivobet
5.10.3 Daivobet/Dovobet/Taclonex – Generic Competition
5.11 Soriatane (acitretin, GSK)
5.11.1 Soriatane: Sales Forecast 2014-2024
5.12 Psoriasis Drugs Market: Summary
6. Skin Infection Drugs Market 2014-2024
6.1 Skin Infection Drugs: A Growing Submarket
6.2 Leading Products in the Skin Infections Drug Market in 2012 and 2013
6.3 Skin Infection Drugs: Market Forecast 2014-2024
6.4 Market Share of Leading Skin Infection Drugs to 2024
6.5 Cubicin (daptomycin, Cubist Pharmaceuticals)
6.5.1 Cubicin: Sales Forecast 2014-2024
6.5.2 Cubicin Lifecycle Management Strategies
6.5.3 Generic Competition for Cubicin
6.6 Zyvox (linezolid, Pfizer)
6.6.1 Zyvox: Sales Forecast 2014-2024
6.6.2 Tedizolid Threatens Zyvox Market Share
6.7 Valtrex (valaciclovir, GSK)
6.7.1 Valtrex: Sales Forecast 2014-2024
6.8 Canesten (clotrimazole, Bayer)
6.8.1 Canesten: Sales Forecast 2014-2024
6.9 Zovirax (aciclovir, Valeant/GSK)
6.9.1 Zovirax: Sales Forecast 2014-2024
6.9.2 Valeant Acquires Zovirax in US and Canada
6.9.3 Mylan’s Generic Zovirax and Actavis’s Authorised Generic
6.10 Bactroban (mupirocin, GSK)
6.10.1 Bactroban: Sales Forecast 2014-2024
6.11 Lamisil (terbinafine, Novartis)
6.11.1 Lamisil: Sales Forecast 2014-2024
6.11.2 Lamisil Sales Affected by Novartis Manufacturing Problems
6.12 Skin Infection Drugs Market: Summary
7. Acne Drugs Market 2014-2024
7.1 Drugs for Acne: A Highly Fragmented Market
7.2 Leading Products in the Acne Drug Market in 2012 and 2013
7.3 Acne Drugs: Trends and Developments
7.3.1 Combination Treatments for Acne
7.3.2 Oral Contraceptives in Treating Acne
7.3.3 Generic Competition in the Acne Drugs Market
7.4 Acne Drugs: Market Forecast 2014-2024
7.5 Market Share of Leading Acne Drugs to 2024
7.6 Solodyn (minocycline, Valeant)
7.6.1 Solodyn: Sales Forecast 2014-2024
7.6.2 Antitrust Action over Solodyn Pay-For-Delay Deals
7.6.3 Impax and Medicis Collaborating on Advanced Solodyn
7.6.4 Medicis and Lupin Settle
7.7 Claravis (isotretinoin, Teva)
7.7.1 Claravis: Sales Forecast 2014-2024
7.8 Epiduo (adapalene/benzoyl peroxide, Galderma)
7.8.1 Epiduo: Sales Forecast 2014-2024
7.8.2 Galderma and Par Pharmaceutical Settle over Generic Epiduo
7.8.3 Epiduo Approved for Patients Aged 9-11 Years
7.9 Differin (adapalene, Galderma)
7.9.1 Differin: Sales Forecast 2014-2024
7.9.2 Federal Circuit Court Invalidates Differin Patents
7.10 Duac (clindamycin/benzoyl peroxide, GSK)
7.10.1 Duac: Sales Forecast 2014-2024
7.11 Aczone (dapsone, Allergan)
7.11.1 Aczone: Sales Forecast 2014-2024
7.12 Amnesteem (isotretinoin, Mylan)
7.12.1 Amnesteem: Sales Forecast 2014-2024
7.13 Doryx (doxycycline, Actavis)
7.13.1 Doryx: Sales Forecast 2014-2024
7.13.2 Warner Chilcott’s Lifecycle Management Strategies
7.13.3 Generic Competition for Doryx
7.14 Ziana (clindamycin/tretinoin, Valeant)
7.14.1 Ziana: Sales Forecast 2014-2024
7.14.2 Actavis to Launch Generic Ziana in 2016
7.15 Acanya (clindamycin/benzoyl peroxide, Dow/Valeant)
7.15.1 Acanya: Sales Forecast 2014-2024
7.15.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
7.15.3 Dow/Valeant File Suit Against Perrigo’s ANDA
7.16 Absorica/Epuris (CIP-isotretinoin, Cipher)
7.16.1 Absorica/Epuris: Sales Forecast 2014-2024
7.17 Other Products
7.17.1 Diane (cyproterone/ethinyl estradiol, Bayer)
7.17.2 Veltin (tretinoin/clindamycin, GSK)
7.18 Acne Drugs Market: Summary
8. Dermatitis Drugs Market 2014-2024
8.1 Dermatitis Drugs: High Generic Penetration
8.2 Leading Products in the Dermatitis Drug Market in 2012 and 2013
8.3 Dermatitis Drugs: Market Forecast 2014-2024
8.4 Market Share of Leading Dermatitis Drugs to 2024
8.5 Bepanthen (dexpanthenol, Bayer)
8.5.1 Bepanthen: Sales Forecast 2014-2024
8.6 Protopic (tacrolimus, Astellas Pharma/Roche)
8.6.1 Protopic: Sales Forecast 2014-2024
8.6.2 Protopic Benefits from Expanded Indication
8.6.3 Generic Competition for Protopic
8.7 Elocon (mometasone, Merck & Co.)
8.7.1 Elocon: Sales Forecast 2014-2024
8.8 Elidel (pimecrolimus, Meda/Valeant)
8.8.1 Elidel: Sales Forecast 2014-2024
8.9 Dermatitis Drugs Market: Summary
9. Leading Companies in the Dermatological Drugs Market
9.1 Galderma
9.1.1 Galderma: Dermatological Drugs Product Portfolio
9.1.2 Galderma: Sales Forecast 2014-2024
9.1.3 Galderma: Products in Development
9.1.3.1 NVC-422 (auriclosene) for Rosacea
9.1.4 Galderma: Recent Developments
9.1.4.1 Nestlé Acquires 100% of Galderma
9.1.4.2 Galderma Laboratories Restructuring
9.1.4.3 Mirvaso Launched for Rosacea
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio
9.2.2 Johnson & Johnson: Sales Forecast 2014-2024
9.2.3 Johnson & Johnson: Products in Development
9.3 AbbVie
9.3.1 AbbVie: Dermatological Drugs Product Portfolio
9.3.2 AbbVie: Sales Forecast 2014-2024
9.3.3 AbbVie: Products in Development
9.3.3.1 BT-061 (tregalizumab) for Psoriasis
9.4 GSK
9.4.1 GSK: Dermatological Drugs Product Portfolio
9.4.2 GSK: Sales Forecast 2014-2024
9.4.3 GSK: Products in Development
9.4.4 GSK: Recent Developments
9.4.4.1 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.4.4.2 GSK’s China Corruption Probe
9.5 Pfizer
9.5.1 Pfizer: Dermatological Drugs Product Portfolio
9.5.2 Pfizer: Sales Forecast 2014-2024
9.5.3 Pfizer: Products in Development
9.6 LEO Pharma
9.6.1 LEO Pharma: Dermatological Drugs Product Portfolio
9.6.2 LEO Pharma: Sales Forecast 2014-2024
9.6.3 LEO Pharma: Products in Development
10. Dermatological Drugs Pipeline Analysis 2014-2024
10.1 New Technology in R&D Pipeline Activities
10.1.1 Reformulation
10.1.2 Combination Treatments
10.1.3 New Mechanisms and Drug Delivery Technologies
10.1.4 Potential Market Entrants
10.2 Psoriasis: Filed or Recently Launched
10.2.1 Cimzia (certolizumab, UCB)
10.2.2 Sorilux (calcipotriene foam, GSK)
10.3 Psoriasis: Phase 3 Pipeline
10.3.1 000-0551 Lotion (halobetasol, Therapeutics, Inc.)
10.3.2 AIN457 (secukinumab, Novartis)
10.3.3 AMG827 (brodalumab, AstraZeneca/Amgen)
10.3.4 CF101 (IB-MECA, Can-Fite BioPharma)
10.3.5 LAS41008 (dimethyl fumarate , Almirall)
10.3.6 LEO 90100 (LEO Pharma)
10.3.7 LY2439821 (ixekizumab, Eli Lilly)
10.3.8 MK-3222/SCH 900222 (tildrakizumab, Merck)
10.3.9 Otezla (apremilast, Celgene)
10.3.10 STF 115469 (calcipotriene foam, GSK)
10.3.11 Xeljanz (tofacitinib, Pfizer)
10.4 Psoriasis: Phase 2 Pipeline
10.4.1 AN2728 (PDE-4 inhibitor, Anacor Pharmaceuticals)
10.4.2 CNTO 1959 (guselkumab, MorphoSys/Janssen)
10.4.3 CT327 (TrkA inhibitor, Creabilis Therapeutics)
10.4.4 ASP015K (JAK inhibitor, Janssen/Astellas)
10.4.5 Jakavi/Jakafi (ruxolitinib, Incyte/Novartis)
10.4.6 LY3009104 (baricitinib, Incyte/Eli Lilly)
10.4.7 PH-10 (Rose bengal, Provectus Biopharmaceuticals)
10.5 Psoriasis: Phase 1 and Preclinical Pipeline
10.6 Psoriasis: Recently Terminated Drugs
10.6.1 Ozespa (briakinumab, Abbott)
10.6.2 AEB071 (sotrastaurin, Novartis)
10.6.3 Voclera (voclosporin, Aurinia)
10.7 Skin Infections: Phase 3 Pipeline
10.7.1 AN2690 (tavaborole, Anacor)
10.7.2 Dalvance (dalbavancin, Durata Therapeutics)
10.7.3 Delafloxacin (delafloxacin, Melinta Pharmaceuticals)
10.7.4 Jublia (efinaconazole, Valeant)
10.7.5 NB-001 (NanoBio Corporation)
10.7.6 Nuvocid (oritavancin, The Medicines Company)
10.7.7 TR-701 (tedizolid, Cubist)
10.7.8 Luliconazole (Topica Pharmaceuticals)
10.8 Skin Infections: Phase 2 Pipeline
10.9 Skin Infections: Phase 1 and Preclinical Pipeline
10.10 Acne: Phase 3 Pipeline
10.10.1 Duac low dose (clindamycin/benzoyl peroxide, GSK)
10.10.2 Visonac (photodynamic therapy, Photocure)
10.11 Acne: Phase 2 Pipeline
10.12 Acne: Phase 1 and Preclinical Pipeline
10.12.1 Acne Vaccine – A Treatment for the Future?
10.13 Dermatitis: Phase 3 Pipeline
10.13.1 Toctino (alitretinoin, GSK)
10.13.2 Dermadexin and Pruridexin (P3CGM, Astion Pharma)
10.13.3 Dexeryl Cream (glycerol/paraffin emollient, Pierre Fabre)
10.13.4 Soriatane (acitretin, InnovaDerm/Tribute Pharmaceuticals)
10.14 Dermatitis: Phase 2 Pipeline
10.14.1 REGN668/SAR231893 (dupilumab, Regeneron/Sanofi)
10.15 Dermatitis: Phase 1 and Preclinical Pipeline
10.16 Other Dermatological Drugs: Filed or Recently Launched
10.16.1 Actikerall (fluorouracil/salicylic acid, Almirall)
10.16.2 Ameluz (5-ALA photodynamic therapy, Biofrontera)
10.16.3 Mirvaso (brimonidine, Galderma)
10.16.4 Picato (ingenol mebutate, LEO Pharma)
10.16.5 Xolair (omalizumab, Novartis/Roche)
10.17 Other Dermatological Drugs: Phase 3 Pipeline
10.17.1 Atralin (tretinoin, Valeant)
10.17.2 BMS-936558 (nivolumab, Bristol-Myers Squibb)
10.17.3 CD5024 (ivermectin, Galderma)
10.17.4 Latisse (bimatoprost, Allergan)
10.17.5 LEE011, LGX818 and MEK162 (Novartis)
10.17.6 MK-3475 (lambrolizumab, Merck)
10.17.7 Oleogel-S10 (triterpene extract, Birken)
10.17.8 PV-10 (Rose bengal, Provectus Pharmaceuticals)
10.17.9 SR-T100 gel (Solanum incanum extract, G&E Herbal Biotechnology)
10.17.10 TVEC (talimogene laherparepvec, Amgen)
10.18 Other Dermatological Drugs: Phase 2 Pipeline
10.19 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis of the Dermatological Drugs Market 2014-2024
11.1 SWOT Analysis of the Dermatological Drugs Market
11.2 Strengths
11.2.1 A Strong R&D Pipeline
11.2.2 High Unmet Clinical Need
11.2.3 Strong Industry-Physician Relationships
11.3 Weaknesses
11.3.1 Patient Adherence to Treatment
11.3.2 Limited Efficacy and Adverse Effects
11.3.3 Patent Expiry and Generic Competition
11.4 Opportunities
11.4.1 Growth Areas: Skin Infections, Onychomycosis and Melanoma
11.4.2 Consolidation in the Dermatology Market?
11.4.3 Personalised Dermatology: Technological Advances in Genomics
11.4.4 Advances in Topical Drug Delivery Methods
11.5 Threats
11.5.1 Increasing R&D Costs
11.5.2 Uncertain Reimbursement
11.5.3 Downward Pressures on Drug Prices
11.6 Porter’s Five Forces Analysis of the Dermatological Drugs Market
11.6.1 Rivalry Among Competitors [Medium]
11.6.2 Threat of New Entrants [High]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Medium]
12. Research Interviews
12.1 Interview with Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA
12.1.1 Provectus’ Pipeline: PV-10 and PH-10
12.1.2 The Dermatological Drugs Market
12.2 Interview with Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-Öschelbronn, Germany
12.2.1 Birken’s Pipeline: Oleogel S-10
12.2.2 The Dermatological Drugs Market
12.3 Interview with Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
12.3.1 Psoriasis: Unmet Patent Needs
12.3.2 Leading Dermatology Markets
12.3.3 Patient Adherence is Crucial
12.3.4 The Future of Biological Drug Treatments
12.3.5 Technological and Pipeline Developments
12.3.6 Challenges for Dermatologic Treatments
12.4 Interview with Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG, Leverkusen, Germany
12.4.1 Current State of the Dermatological Drug Market
12.4.2 Biofrontera and Dermatologic Drugs
12.4.3 Future Prospects for the Dermatological Drug Market
12.4.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers
12.4.5 Challenges Facing the Dermatologic Drug Market
12.4.6 Thoughts on Biologics, Small Molecule and Combination Therapies
13. Conclusions
13.1 The World Dermatological Drugs Market in 2012 and 2013
13.1.1 Current Leading Dermatological Drugs Segments
13.1.2 Leading Dermatological Drugs Products
13.1.3 Leading Dermatological Drugs Companies
13.1.4 Leading National Markets
13.2 World Dermatological Drugs Market Forecast 2014-2024
13.3 The Future of the Dermatological Drugs Market?

10.2.2 Sorilux (calcipotriene foam, GSK)
10.3 Psoriasis: Phase 3 Pipeline
10.3.1 000-0551 Lotion (halobetasol, Therapeutics, Inc.)
10.3.2 AIN457 (secukinumab, Novartis)
10.3.3 AMG827 (brodalumab, AstraZeneca/Amgen)
10.3.4 CF101 (IB-MECA, Can-Fite BioPharma)
10.3.5 LAS41008 (dimethyl fumarate , Almirall)
10.3.6 LEO 90100 (LEO Pharma)
10.3.7 LY2439821 (ixekizumab, Eli Lilly)
10.3.8 MK-3222/SCH 900222 (tildrakizumab, Merck)
10.3.9 Otezla (apremilast, Celgene)
10.3.10 STF 115469 (calcipotriene foam, GSK)
10.3.11 Xeljanz (tofacitinib, Pfizer)
10.4 Psoriasis: Phase 2 Pipeline
10.4.1 AN2728 (PDE-4 inhibitor, Anacor Pharmaceuticals)
10.4.2 CNTO 1959 (guselkumab, MorphoSys/Janssen)
10.4.3 CT327 (TrkA inhibitor, Creabilis Therapeutics)
10.4.4 ASP015K (JAK inhibitor, Janssen/Astellas)
10.4.5 Jakavi/Jakafi (ruxolitinib, Incyte/Novartis)
10.4.6 LY3009104 (baricitinib, Incyte/Eli Lilly)
10.4.7 PH-10 (Rose bengal, Provectus Biopharmaceuticals)
10.5 Psoriasis: Phase 1 and Preclinical Pipeline
10.6 Psoriasis: Recently Terminated Drugs
10.6.1 Ozespa (briakinumab, Abbott)
10.6.2 AEB071 (sotrastaurin, Novartis)
10.6.3 Voclera (voclosporin, Aurinia)
10.7 Skin Infections: Phase 3 Pipeline
10.7.1 AN2690 (tavaborole, Anacor)
10.7.2 Dalvance (dalbavancin, Durata Therapeutics)
10.7.3 Delafloxacin (delafloxacin, Melinta Pharmaceuticals)
10.7.4 Jublia (efinaconazole, Valeant)
10.7.5 NB-001 (NanoBio Corporation)
10.7.6 Nuvocid (oritavancin, The Medicines Company)
10.7.7 TR-701 (tedizolid, Cubist)
10.7.8 Luliconazole (Topica Pharmaceuticals)
10.8 Skin Infections: Phase 2 Pipeline
10.9 Skin Infections: Phase 1 and Preclinical Pipeline
10.10 Acne: Phase 3 Pipeline
10.10.1 Duac low dose (clindamycin/benzoyl peroxide, GSK)
10.10.2 Visonac (photodynamic therapy, Photocure)
10.11 Acne: Phase 2 Pipeline
10.12 Acne: Phase 1 and Preclinical Pipeline
10.12.1 Acne Vaccine – A Treatment for the Future?
10.13 Dermatitis: Phase 3 Pipeline
10.13.1 Toctino (alitretinoin, GSK)
10.13.2 Dermadexin and Pruridexin (P3CGM, Astion Pharma)
10.13.3 Dexeryl Cream (glycerol/paraffin emollient, Pierre Fabre)
10.13.4 Soriatane (acitretin, InnovaDerm/Tribute Pharmaceuticals)
10.14 Dermatitis: Phase 2 Pipeline
10.14.1 REGN668/SAR231893 (dupilumab, Regeneron/Sanofi)
10.15 Dermatitis: Phase 1 and Preclinical Pipeline
10.16 Other Dermatological Drugs: Filed or Recently Launched
10.16.1 Actikerall (fluorouracil/salicylic acid, Almirall)
10.16.2 Ameluz (5-ALA photodynamic therapy, Biofrontera)
10.16.3 Mirvaso (brimonidine, Galderma)
10.16.4 Picato (ingenol mebutate, LEO Pharma)
10.16.5 Xolair (omalizumab, Novartis/Roche)
10.17 Other Dermatological Drugs: Phase 3 Pipeline
10.17.1 Atralin (tretinoin, Valeant)
10.17.2 BMS-936558 (nivolumab, Bristol-Myers Squibb)
10.17.3 CD5024 (ivermectin, Galderma)
10.17.4 Latisse (bimatoprost, Allergan)
10.17.5 LEE011, LGX818 and MEK162 (Novartis)
10.17.6 MK-3475 (lambrolizumab, Merck)
10.17.7 Oleogel-S10 (triterpene extract, Birken)
10.17.8 PV-10 (Rose bengal, Provectus Pharmaceuticals)
10.17.9 SR-T100 gel (Solanum incanum extract, G&E Herbal Biotechnology)
10.17.10 TVEC (talimogene laherparepvec, Amgen)
10.18 Other Dermatological Drugs: Phase 2 Pipeline
10.19 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis of the Dermatological Drugs Market 2014-2024
11.1 SWOT Analysis of the Dermatological Drugs Market
11.2 Strengths
11.2.1 A Strong R&D Pipeline
11.2.2 High Unmet Clinical Need
11.2.3 Strong Industry-Physician Relationships
11.3 Weaknesses
11.3.1 Patient Adherence to Treatment
11.3.2 Limited Efficacy and Adverse Effects
11.3.3 Patent Expiry and Generic Competition
11.4 Opportunities
11.4.1 Growth Areas: Skin Infections, Onychomycosis and Melanoma
11.4.2 Consolidation in the Dermatology Market?
11.4.3 Personalised Dermatology: Technological Advances in Genomics
11.4.4 Advances in Topical Drug Delivery Methods
11.5 Threats
11.5.1 Increasing R&D Costs
11.5.2 Uncertain Reimbursement
11.5.3 Downward Pressures on Drug Prices
11.6 Porter’s Five Forces Analysis of the Dermatological Drugs Market
11.6.1 Rivalry Among Competitors [Medium]
11.6.2 Threat of New Entrants [High]
11.6.3 Power of Suppliers [Low]
11.6.4 Power of Buyers [Medium]
11.6.5 Threat of Substitutes [Medium]
12. Research Interviews
12.1 Interview with Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA
12.1.1 Provectus’ Pipeline: PV-10 and PH-10
12.1.2 The Dermatological Drugs Market
12.2 Interview with Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-Öschelbronn, Germany
12.2.1 Birken’s Pipeline: Oleogel S-10
12.2.2 The Dermatological Drugs Market
12.3 Interview with Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
12.3.1 Psoriasis: Unmet Patent Needs
12.3.2 Leading Dermatology Markets
12.3.3 Patient Adherence is Crucial
12.3.4 The Future of Biological Drug Treatments
12.3.5 Technological and Pipeline Developments
12.3.6 Challenges for Dermatologic Treatments
12.4 Interview with Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG, Leverkusen, Germany
12.4.1 Current State of the Dermatological Drug Market
12.4.2 Biofrontera and Dermatologic Drugs
12.4.3 Future Prospects for the Dermatological Drug Market
12.4.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers
12.4.5 Challenges Facing the Dermatologic Drug Market
12.4.6 Thoughts on Biologics, Small Molecule and Combination Therapies
13. Conclusions
13.1 The World Dermatological Drugs Market in 2012 and 2013
13.1.1 Current Leading Dermatological Drugs Segments
13.1.2 Leading Dermatological Drugs Products
13.1.3 Leading Dermatological Drugs Companies
13.1.4 Leading National Markets
13.2 World Dermatological Drugs Market Forecast 2014-2024
13.3 The Future of the Dermatological Drugs Market?

List of Tables
Table 1.1 Currency Exchange Rates, 2012-2013
Table 2.1 Clinical Trial Phases
Table 3.1 Top 10 Dermatological Drugs: Revenue ($m), 2012-2013
Table 3.2 Top 10 Dermatological Drug Manufacturers: Dermatological Drugs Revenue ($m), Market Share (%), 2012-2013
Table 3.3 World Dermatological Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 3.4 Market Shares (%) of Leading Dermatological Drug Market Segments, 2012, 2018 and 2024
Table 4.1 World Dermatological Drugs Market Forecast: Revenues ($m) and Market Shares (%) by National Market, 2012-2013
Table 4.2 World Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2012-2024
Table 4.3 Market Shares (%) of Leading National Dermatological Drugs Markets, 2012, 2018 and 2024
Table 4.4 US Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.5 Japanese Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.6 Chinese Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.7 EU5 Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by National Market, 2012-2024
Table 4.8 German Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.9 French Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.10 UK Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.11 Italian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.12 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.13 Indian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.14 Brazilian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.15 Russian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.16 Mexican Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 5.1 Top 10 Psoriasis Drugs: Revenues ($m), 2012-2013
Table 5.2 Leading Biological Drugs for Psoriasis, 2014
Table 5.3 Psoriasis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2012-2024
Table 5.4 Psoriasis Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 5.5 AbbVie: Humira Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.6 Amgen/Pfizer: Enbrel Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.8 Johnson & Johnson: Remicade Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.9 LEO Pharma: Daivobet Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.10 GSK: Soriatane Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.1 Top 5 Skin Infection Drugs: Revenues ($m), 2012-2013
Table 6.2 Skin Infection Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2012-2024
Table 6.3 Skin Infection Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 6.4 Cubist: Cubicin Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.5 Pfizer: Zyvox Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.6 GSK: Valtrex Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.7 Bayer: Canesten Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.8 Valeant/GSK: Zovirax Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.9 GSK: Bactroban Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.10 Novartis: Lamisil Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.1 Top 10 Acne Drugs: Revenues ($m), 2012-2013
Table 7.2 Acne Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2012-2024
Table 7.3 Acne Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 7.4 Valeant: Solodyn Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.5 Teva: Claravis Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.6 Galderma: Epiduo Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.7 Galderma: Differin Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.8 GSK: Duac Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.9 Allergan: Aczone Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.10 Mylan: Amnesteem Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.11 Actavis: Doryx Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.12 Valeant: Ziana Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.13 Valeant: Acanya Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.14 Cipher: Absorica Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 8.1 Top 4 Dermatitis Drugs: Revenues ($m), 2012-2013
Table 8.2 Dermatitis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2012-2024
Table 8.3 Dermatitis Drugs Market: Market Shares (%) by Drug, 2013, 2018 and 2024
Table 8.4 Bayer: Bepanthen Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 8.5 Astellas: Protopic Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 8.6 Merck & Co.: Elocon Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 8.7 Meda/Valeant: Elidel ($m), AGR (%), CAGR (%), 2012-2024
Table 9.1 Galderma: Overview, 2012-2013
Table 9.2 Galderma: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.3 Johnson & Johnson: Overview, 2012-2013
Table 9.4 Johnson & Johnson: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.5 AbbVie: Overview, 2012-2013
Table 9.6 AbbVie: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.7 GSK: Overview, 2012-2013
Table 9.8 GSK: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.9 GSK: Dermatological Drugs Pipeline, 2014
Table 9.10 Pfizer: Overview, 2012-2013
Table 9.11 Pfizer: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.12 LEO Pharma: Overview, 2012-2013
Table 9.13 LEO Pharma: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 9.14 LEO Pharma: Dermatological Drugs Pipeline, 2014
Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 10.4 Skin Infection Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.5 Skin Infection Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2014
Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2014
Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2014
Table 10.13 Other Dermatological Drugs Pipeline: Phase 1 and Preclinical Drugs, 2014
Table 11.1 SWOT Analysis of the Dermatological Drugs Market, 2014-2024
List of Figures
Figure 2.1 Anatomy of Human Skin, 2014
Figure 3.1 Top 10 Dermatological Drugs: Market Share (%), 2013
Figure 3.2 Top 10 Dermatological Drug Manufacturers: Market Share (%), 2013
Figure 3.3 World Dermatological Drugs Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 3.4 World Dermatological Drugs Market: Market Shares (%) by Segment, 2012
Figure 3.5 World Dermatological Drugs Market: Market Shares (%) by Segment, 2018
Figure 3.6 World Dermatological Drugs Market: Market Shares (%) by Segment, 2024
Figure 3.7 World Dermatological Drugs Market: Drivers and Restraints, 2014-2024
Figure 4.1 World Dermatological Drugs Market: Revenues ($m) by National Market, 2013
Figure 4.2 World Dermatological Drugs Market: Market Shares (%) by National Market, 2013
Figure 4.3 World Dermatological Drugs Market: Revenues ($m) by National Market, 2012-2024
Figure 4.4 World Dermatological Drugs Market: Market Shares (%) by National Market, 2012
Figure 4.5 World Dermatological Drugs Market: Market Shares (%) by National Market, 2018
Figure 4.6 World Dermatological Drugs Market: Market Shares (%) by National Market, 2024
Figure 4.7 US Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.8 Japanese Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.9 Chinese Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.10 EU5 Dermatological Drugs Market: Revenues ($m) by National Market, 2012-2024
Figure 4.11 German Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.12 French Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.13 UK Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.14 Italian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.15 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.16 Indian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.17 Brazilian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.18 Russian Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 4.19 Mexican Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024
Figure 5.1 Psoriasis Drugs Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.2 Psoriasis Drugs Market: Market Shares (%) by Drug, 2013
Figure 5.3 Psoriasis Drugs Market: Market Shares (%) by Drug, 2018
Figure 5.4 Psoriasis Drugs Market: Market Shares (%) by Drug, 2024
Figure 5.5 AbbVie: Humira Revenue ($m), AGR (%), 2012-2024
Figure 5.6 Amgen/Pfizer: Enbrel Revenue ($m), AGR (%), 2012-2024
Figure 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), 2012-2024
Figure 5.8 Johnson & Johnson: Remicade Revenue ($m), AGR (%), 2012-2024
Figure 5.9 LEO Pharma: Daivobet Revenue ($m), AGR (%), 2012-2024
Figure 5.10 GSK: Soriatane Revenue ($m), AGR (%), 2012-2024
Figure 6.1 Skin Infection Drugs Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.2 Skin Infection Drugs Market: Market Shares (%) by Drug, 2013
Figure 6.3 Skin Infection Drugs Market: Market Shares (%) by Drug, 2018
Figure 6.4 Skin Infection Drugs Market: Market Shares (%) by Drug, 2024
Figure 6.5 Cubist: Cubicin Revenue ($m), AGR (%), 2012-2024
Figure 6.6 Pfizer: Zyvox Revenue ($m), AGR (%), 2012-2024
Figure 6.7 GSK: Valtrex Revenue ($m), AGR (%), 2012-2024
Figure 6.8 Bayer: Canesten Revenue ($m), AGR (%), 2012-2024
Figure 6.9 Valeant/GSK: Zovirax Revenue ($m), AGR (%), 2012-2024
Figure 6.10 GSK: Bactroban Revenue ($m), AGR (%), 2012-2024
Figure 6.11 Novartis: Lamisil Revenue ($m), AGR (%), 2012-2024
Figure 7.1 Acne Drugs Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 7.2 Acne Drugs Market: Market Shares (%) by Drug, 2013
Figure 7.3 Acne Drugs Market: Market Shares (%) by Drug, 2018
Figure 7.4 Acne Drugs Market: Market Shares (%) by Drug, 2024
Figure 7.5 Valeant: Solodyn Revenue ($m), AGR (%), 2012-2024
Figure 7.6 Teva: Claravis Revenue ($m), AGR (%), 2012-2024
Figure 7.7 Galderma: Epiduo Revenue ($m), AGR (%), 2012-2024
Figure 7.8 Galderma: Differin Revenue ($m), AGR (%), 2012-2024
Figure 7.9 GSK: Duac Revenue ($m), AGR (%), 2012-2024
Figure 7.10 Allergan: Aczone Revenue ($m), AGR (%), 2012-2024
Figure 7.11 Mylan: Amnesteem Revenue ($m), AGR (%), 2012-2024
Figure 7.12 Actavis: Doryx Revenue ($m), AGR (%), 2012-2024
Figure 7.13 Valeant: Ziana Revenue ($m), AGR (%), 2012-2024
Figure 7.14 Valeant: Acanya Revenue ($m), AGR (%), 2012-2024
Figure 7.15 Cipher: Absorica Revenue ($m), AGR (%), 2012-2024
Figure 8.1 Dermatitis Drugs Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 8.2 Dermatitis Drugs Market: Market Shares (%) by Drug, 2013
Figure 8.3 Dermatitis Drugs Market: Market Shares (%) by Drug, 2018
Figure 8.4 Dermatitis Drugs Market: Market Shares (%) by Drug, 2024
Figure 8.5 Bayer: Bepanthen Revenue ($m), AGR (%), 2012-2024
Figure 8.6 Astellas: Protopic Revenue ($m), AGR (%), 2012-2024
Figure 8.7 Merck & Co.: Elocon Revenue ($m), AGR (%), 2012-2024
Figure 8.8 Meda/Valeant: Elidel Revenue ($m), AGR (%), 2012-2024
Figure 9.1 Galderma: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 9.2 Johnson & Johnson: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 9.3 AbbVie: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 9.4 GSK: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 9.5 Pfizer: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 9.6 LEO Pharma: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024
Figure 11.1 Porter’s Five Forces Analysis of the Dermatological Drugs Market, 2014-2024

【掲載企業】

Abbott (split from Abbott Laboratories)
AbbVie
AbGenomics
Actavis
Actelion
AET BioTech
Affinium
AiCuris
Alembic
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Corp
AnGes MG
Anterios
Apeiron Biologics
ApoPharma
Ascend Therapeutics
Astellas
Astion Pharma
AstraZeneca
Asubio Pharma (part of Daiichi Sankyo)
Atrix Laboratories (acquired by QLT Inc.)
Aurinia (formerly Isotechnika)
Aurobindo Pharma
Ausio Pharmaceuticals
Barr Laboratories (part of Teva)
Basilea Pharmaceutica
Bayer
Berg Pharma
Bertek Pharmaceuticals (part of Mylan)
Biocon
Biofrontera
Biotest AG
Biovail Laboratories (part of Valeant)
BioVex Group (acquired by Amgen)
BioXpress Therapeutics
Birken AG
Boehringer Ingelheim
Braintree Laboratories
Bristol-Myers Squibb
Bübchen (division of Nestlé)
Cadila Healthcare (part of Zydus Cadila)
CalciMedica
Can-Fite BioPharma
Cardinal Health
Causa Research
Celgene
Cellceutix
Celltech (acquired by UCB Pharma)
Celltrion
Celsus Therapeutics
Cempra
Centocor Ortho Biotech (part of Johnson & Johnson)
Cipher Pharmaceuticals
Cipla
Circassia
CollaGenex (acquired by Galderma)
Compañía Internacional de Comercio, S.A.P.I. de C.V. (CISCA) (acquired by Taisho)
Convoy Therapeutics
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist Pharmaceuticals
Cutanea Life Sciences
Daiichi Sankyo
DAVA Pharmaceuticals
Delenex Therapeutics
Dermik (Sanofi division acquired by Valeant)
Dermira Inc.
Dow Pharmaceutical Sciences (part of Valeant)
Dr. Reddy's Laboratories
Durata Therapeutics
Eisai
Eli Lilly
Elorac
Foamix
Fortuderm
Forward Pharma
Fougera Pharmaceuticals (acquired by Novartis)
Fujifilm
Fujisawa Healthcare
Furiex Pharmaceuticals
G&E Herbal Biotechnology
G&W Laboratories
Galderma (now part of Nestlé)
Galderma Laboratories (US subsidiary of Galderma)
Gene Signal
Genentech (subsidiary of Roche)
Genpharm
Genzyme (subsidiary of Sanofi)
Glenmark Pharmaceuticals
Grupo Imperial (acquired by Taisho)
GSK
Hanwha Pharma
Heritage Pharmaceuticals
Hospira
Human Genome Sciences (subsidiary of GSK)
Idera Pharmaceuticals
Immune Response BioPharma, Inc.
Immunex (acquired by Amgen)
Impax Laboratories
Incyte
Innovaderm Research
Instituto Terapeutico Delta Ltda (acquired by Valeant)
Intrepid Therapeutics
Janssen (part of Johnson & Johnson)
Janssen Biotech (part of Johnson & Johnson)
Johnson & Johnson
Jubilant Life Sciences
Kosei (acquired by Taisho)
Kuhnil Pharma
KV Pharmaceutical
Kyowa Hakko Kirin
Laboratorios Kendrick (acquired by Sanofi)
LEO Foundation (LEO Pharma holding company)
LEO Pharma
L'Oréal
Lupin
Maruho
Matrix Laboratories (part of Mylan)
Mayne Pharma
McNeil Consumer Healthcare (part of Johnson & Johnson)
Meda AB
Medicis (part of Valeant)
Medison Pharma
Melinta Pharmaceuticals (formerly Rib-X)
Merck & Co.
Mitsubishi Tanabe
Moleculin
MorphoSys
Mycenax Biotech
Mylan Pharmaceuticals
Nabriva Therapeutics
NanoBio Corporation
Nestlé
NovaBay Pharmaceuticals
Novartis
Nycomed (part of Takeda)
OphthaliX (subsidiary of Can-Fite BioPharma)
Par Pharmaceutical
Paratek Pharmaceuticals
Peplin (acquired by LEO Pharma)
Perrigo
Pfizer
Pharmacia (part of Pfizer)
PharmaPraxis
Photocure
Pierre Fabre Medicament
Pliva Hrvatska (part of Teva)
PreCision Dermatology (acquired by Valeant)
Provectus Biopharmaceuticals
QLT Inc.
Q-Med (acquired by Galderma)
Ranbaxy (now part of Sun Pharma)
Regeneron
Roche
Rochester Drug Cooperative
Roxane Laboratories (part of Boehringer Ingelheim)
Sandoz (division of Novartis)
SangStat
Sanofi
Sanofi-Pasteur (vaccines division of Sanofi)
Schering-Plough (acquired by Merck & Co.)
Shanghai Celgen Bio-pharmaceutical
Shanghai CP Guojian Pharmaceutical
Shape Pharmaceuticals
Shionogi
Sidmak Laboratories
Sol-Gel Technologies
Stiefel Laboratories (acquired by GSK)
Sunovion Pharmaceuticals (part of Dainippon Sumitomo)
Switch Biotech
Synthes Inc. (part of Johnson & Johnson)
Taisho
Takeda Pharmaceuticals
Targanta Therapeutics (acquired by The Medicines Company)
Taro Pharmaceutical Industries
Tecnofarma (acquired by Valeant)
Telormedix
Teva
The Medicines Company
Therapeutics, Inc.
Theravance
Tolmar Inc.
Topica Pharmaceuticals
Tribute Pharmaceuticals
Trius Therapeutics (acquired by Cubist)
TTY BioPharm
UCB Pharma
Valeant
Vatera Healthcare Partners
VBL Therapeutics
Vicuron (acquired by Durata)
Vidara Therapeutics
ViiV Healthcare (GSK/Pfizer joint venture)
ViroBay
Vitacilina Corporation of America (VitaCorp) (acquired by Taisho)
Warner Chilcott (acquired by Actavis)
Watson Laboratories (part of Actavis)
Watson Pharmaceuticals (now Actavis)
Welichem Biotech
Wockhardt
Wyeth (part of Pfizer)
XBiotech
XenoPort
Xoma
Zydus Cadila

【レポートのキーワード】

皮膚科治療薬、皮膚病薬

★調査レポート[皮膚科治療薬市場（2014-2024）] ( Dermatological Drugs Market Forecast 2014-2024 / Visiongain-405316) 販売に関する免責事項

[皮膚科治療薬市場（2014-2024）] ( Dermatological Drugs Market Forecast 2014-2024 / Visiongain-405316) についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆